Physician profile
David William Powell
NPI 1295701456
$10,231.02
in general payments reported to CMS, 2019-2025
36 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $358 · 2021: $1,352 · 2022: $1,407 · 2023: $2,000 · 2024: $1,376 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,267 · Education: $17.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,266.87 |
| Education | $17.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,810.45 | 2019-2025 | |
| Genzyme Corporation | $1,449.23 | 2019-2025 | |
| Lilly USA, LLC | $952.46 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $915.45 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $689.32 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $591.26 | 2019-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $481.61 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $416.82 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $359.77 | 2019-2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $324.52 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $287.11 | 2022-2025 | Sotyktu |
| Allergan, INC. | $203.99 | 2019-2022 | |
| Leo Pharma INC. | $194.35 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $166.27 | 2019-2024 | Cimzia, Bimzelx |
| Biofrontera INC. | $166.04 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $138.75 | 2019-2025 | |
| Incyte Corporation | $118.83 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $111.25 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Dermavant Sciences, INC. | $108.21 | 2022-2024 | Vtama |
| Celgene Corporation | $107.37 | 2019 | |
| Epi Health, LLC | $84.48 | 2019 | |
| Hill Dermaceuticals, INC. | $81.48 | 2021-2024 | Tolak |
| Boston Scientific Corporation | $66.96 | 2025 | Ams 800 Artificial Urinary Sphincter |
| Mayne Pharma Commercial LLC | $63.30 | 2019 | |
| Almirall LLC | $60.50 | 2019-2025 | Klisyri |
| Organon LLC | $48.20 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $42.88 | 2020 | |
| Botanix Sb INC | $40.26 | 2025 | Sofdra |
| Ani Pharmaceuticals, INC. | $31.70 | 2023 | Apexicon E |
| Merck Sharp & Dohme LLC | $26.47 | 2019 | |
| Dermira, INC. | $23.97 | 2021 | |
| Strata Skin Sciences, INC. | $20.30 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $17.18 | 2024 | Clindacin Etz |
| Sebela Pharmaceuticals INC. | $15.63 | 2019 | |
| Kyowa Kirin, INC. | $12.40 | 2021 | |
| Journey Medical Corporation | $2.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.